Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...

Ausführliche Beschreibung

Bibliographische Detailangaben

Autoren:	Horvath, Dennis, Termperton, Nigel, Mayora-Neto, Martin, Da Costa, Kelly, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, Groettrup, Marcus, Hoschuetzky, Heinz, Rohayem, Jacques, ter Meulen, Jan,
Format:	Artikel
Sprache:	Englisch
Veröffentlicht:	Philipps-Universität Marburg 2023
Schlagworte:	Medizin Biotechnology Immunology Microbiology Medical sciences Medicine
Online-Zugang:	PDF-Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!